Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of CAD 183.82 billion. The enterprise value is 205.93 billion.

Market Cap	183.82B
Enterprise Value	205.93B

Important Dates

The next estimated earnings date is Friday, August 1, 2025.

Earnings Date	Aug 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.28%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 21.44 and the forward PE ratio is 13.14.

PE Ratio	21.44
Forward PE	13.14
PS Ratio	4.45
PB Ratio	6.70
P/TBV Ratio	n/a
P/FCF Ratio	12.99
P/OCF Ratio	12.34
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.84, with an EV/FCF ratio of 14.55.

EV / Earnings	24.02
EV / Sales	5.24
EV / EBITDA	10.84
EV / EBIT	13.74
EV / FCF	14.55

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 1.31.

Current Ratio	1.37
Quick Ratio	1.06
Debt / Equity	1.31
Debt / EBITDA	1.80
Debt / FCF	2.53
Interest Coverage	11.14

Financial Efficiency

Return on equity (ROE) is 32.66% and return on invested capital (ROIC) is 15.79%.

Return on Equity (ROE)	32.66%
Return on Assets (ROA)	12.14%
Return on Invested Capital (ROIC)	15.79%
Return on Capital Employed (ROCE)	24.84%
Revenue Per Employee	2.35M
Profits Per Employee	487,147
Employee Count	17,600
Asset Turnover	0.51
Inventory Turnover	3.45

Taxes

In the past 12 months, Gilead Sciences has paid 1.24 billion in taxes.

Income Tax	1.24B
Effective Tax Rate	12.60%

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	53.72
Average Volume (20 Days)	4,896

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.54

Income Statement

In the last 12 months, Gilead Sciences had revenue of CAD 41.30 billion and earned 8.57 billion in profits. Earnings per share was 6.80.

Revenue	41.30B
Gross Profit	32.33B
Operating Income	15.74B
Pretax Income	9.81B
Net Income	8.57B
EBITDA	19.73B
EBIT	15.74B
Earnings Per Share (EPS)	6.80

Full Income Statement

Balance Sheet

The company has 12.52 billion in cash and 35.86 billion in debt, giving a net cash position of -23.34 billion.

Cash & Cash Equivalents	12.52B
Total Debt	35.86B
Net Cash	-23.34B
Net Cash Per Share	n/a
Equity (Book Value)	27.42B
Book Value Per Share	22.12
Working Capital	6.55B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 14.90 billion and capital expenditures -750.30 million, giving a free cash flow of 14.15 billion.

Operating Cash Flow	14.90B
Capital Expenditures	-750.30M
Free Cash Flow	14.15B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.29%, with operating and profit margins of 38.11% and 20.76%.

Gross Margin	78.29%
Operating Margin	38.11%
Pretax Margin	23.75%
Profit Margin	20.76%
EBITDA Margin	47.76%
EBIT Margin	38.11%
FCF Margin	34.26%

Dividends & Yields

Gilead Sciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	66.02%
Buyback Yield	-0.28%
Shareholder Yield	n/a
Earnings Yield	4.66%
FCF Yield	7.70%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.19 and a Piotroski F-Score of 7.

Altman Z-Score	3.19
Piotroski F-Score	7